Abstract:BACKGROUND:Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood.METHODS:For a comprehensive analysis of the tumor microenvironment in cholangiocarcinoma, we performed multiplex immunohistochemistry with two 15-marker immune panels and Nanostring assays for a comprehensive analysis of 104 surgically resected cholangiocarcinomas including intrahepatic, hilar, and distal cholangiocarcinoma. We also validated some key findings with a batch integration analysis of published single cell RNA sequencing data.RESULTS:This study found that natural killer cells occupy the largest immune cell compartment in cholangiocarcinoma. Granzyme-B+CD8+ effector T cells are significantly associated with better overall survival in both intrahepatic and distal cholangiocarcinoma. Above 85% of intrahepatic cholangiocarcinomas with higher density of PD-1-EOMES-CD8+ effector T cells are associated with long-term survival. However, only the density of PD-1-EOMES-CD8+ T cells in the tumor areas, but not in the peripheries of the tumors, is prognostic. In all three cholangiocarcinoma subtypes, T regulator cells are significantly associated with a poor prognosis; however, M1 and M2 tumor-associated macrophages or PD-L1+ tumor-associated macrophage demonstrate different prognostic values. Combining PD-L1+ M1 or M2, PD-L1- M1 or M2 tumor-associated macrophages, and T regulator cells to subgroup intrahepatic and distal cholangiocarcinoma, the prognosis is significantly better distinguished. Moreover, PD-L1- M2 tumor-associated macrophages is associated with a good prognosis in intrahepatic and distal cholangiocarcinoma, suggesting this subtype of M2 tumor-associated macrophages may be antitumoral. Interestingly, lower densities of various types of immunosuppressive cells are associated with decreased infiltration of effector T cells in distal and hilar cholangiocarcinoma, but not in intrahepatic cholangiocarcinoma. In intrahepatic cholangiocarcinoma, PD-L1+ tumor-associated macrophages exert their immunosuppressive function likely through promoting T cell exhaustion.CONCLUSIONS:This study suggests that the densities of Granzyme-B+CD8+ effector T cells and non-exhausted PD-1-EOMES-CD8+ T cells and the PD-L1 status in the tumor-associated macrophages are prognostic makers in cholangiocarcinomas. The study also supports targeting PD-L1+ tumor-associated macrophages as the immunotherapy for cholangiocarcinoma.

Immunotherapy and Targeted Therapy for Cholangiocarcinoma: Artificial Intelligence Research in Imaging

Artificial intelligence and cholangiocarcinoma: Updates and prospects

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers

Artificial Intelligence in Medical Imaging for Cholangiocarcinoma Diagnosis: A Systematic Review with Scientometric Analysis

Immune Cell Atlas of Cholangiocarcinomas Reveals Distinct Tumor Microenvironments and Associated Prognoses.

Progress of immunotherapy of cholangiocarcinoma

Application of AI on cholangiocarcinoma

Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy.

Preclinical and Clinical Studies of Immunotherapy for the Treatment of Cholangiocarcinoma

Long Survival after Immunotherapy Plus Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature

Immunotherapy in Cholangiocarcinoma: from Concept to Clinical Trials

Research progress on immunotherapy targeting the tumor immune microenvironment for cholangiocarcinoma

Tumor Immune Microenvironment and the Current Immunotherapy of Cholangiocarcinoma (Review)

Augmenting care in hepatocellular carcinoma with artificial intelligence

Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions

Targeted Mutation-Based Therapy for Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches

Application of artificial intelligence to hepatobiliary cancer clinical outcomes research

Advances in targeted therapy of cholangiocarcinoma

MRI‐Based Radiomics and Deep Learning in Biological Characteristics and Prognosis of Hepatocellular Carcinoma: Opportunities and Challenges